Chelsie L. Fleischer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Chelsie L. Fleischer has a total of 120 co-authors. Here are the top co-authors by number of shared publications:
- Kevin D. Deane
Division of Rheumatology, University of Colorado Anschutz School of Medicine, Aurora, USA
3 shared publications Elizabeth A. Bemis
University of Colorado Denver
2 shared publications- Jennifer Seifert
Division of Rheumatology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
2 shared publications - Mary Kristen Demoruelle
University of Colorado Anschutz Medical Campus
2 shared publications - Adam K. Savage
Allen Institute for Immunology, Seattle, WA, USA
1 shared publication - Adrie Van Bokhoven
Department of Pathology, University of Colorado Denver, Anschutz Medical Campus; Aurora, CO, 80045, USA
1 shared publication
Latest Publications
- Top Cited Papers
- 24 September 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (817) , eadt7214
Progression to rheumatoid arthritis in at-risk individuals is defined by systemic inflammation and by T and B cell dysregulation
Rheumatoid arthritis (RA) is preceded by an at-risk stage of disease that can be marked by the presence of anticitrullinated protein antibodies (ACPAs) but the absence of clinically apparent synovitis (clinical RA). Preemptive intervention in at-risk individuals could prevent or delay future tissue damage; however, the immunobiology of this stage is unclear. Using integrative multiomics, we longitudinally profiled at-risk individuals, where one-third of participants developed clinical RA on study. We found evidence of systemic inflammation and signatures of activation in naïve T and B cells of at-risk individuals. During progression to clinical RA, proinflammatory skewing of atypical B cells and expansion of memory CD4 T cells with signatures of activation and B cell help were present without elevations in circulating ACPA titers. Epigenetic changes in naïve CD4 T cells suggested a predisposition to differentiate into effector cells capable of B cell help. These findings characterize pathogenesis of the ACPA + at-risk stage and support the concept that the disease begins much earlier than clinical RA. Additionally, an extensive immune resource of the at-risk stage and progression to clinical RA with interactive tools was developed to enable further investigation.
- 24 September 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (817) , eadt7214
Top Cited PapersProgression to rheumatoid arthritis in at-risk individuals is defined by systemic inflammation and by T and B cell dysregulation
Rheumatoid arthritis (RA) is preceded by an at-risk stage of disease that can be marked by the presence of anticitrullinated protein antibodies (ACPAs) but the absence of clinically apparent synovitis (clinical RA). Preemptive intervention in at-risk individuals could prevent or delay future tissue damage; however, the immunobiology of this stage is unclear. Using integrative multiomics, we longitudinally profiled at-risk individuals, where one-third of participants developed clinical RA on study. We found evidence of systemic inflammation and signatures of activation in naïve T and B cells of at-risk individuals. During progression to clinical RA, proinflammatory skewing of atypical B cells and expansion of memory CD4 T cells with signatures of activation and B cell help were present without elevations in circulating ACPA titers. Epigenetic changes in naïve CD4 T cells suggested a predisposition to differentiate into effector cells capable of B cell help. These findings characterize pathogenesis of the ACPA + at-risk stage and support the concept that the disease begins much earlier than clinical RA. Additionally, an extensive immune resource of the at-risk stage and progression to clinical RA with interactive tools was developed to enable further investigation.
- Open Access
- 1 March 2024
- Published by Oxford University Press (OUP) in ImmunoHorizons
- Vol. 8 (3) , 254-268
SARS-CoV-2 Vaccine-Elicited Immunity after B Cell Depletion in Multiple Sclerosis
The impact of B cell deficiency on the humoral and cellular responses to SARS-CoV2 mRNA vaccination remains a challenging and significant clinical management question. We evaluated vaccine-elicited serological and cellular responses in 1) healthy individuals who were pre-exposed to SARS-CoV-2 (n = 21), 2) healthy individuals who received a homologous booster (mRNA, n = 19; or Novavax, n = 19), and 3) persons with multiple sclerosis on B cell depletion therapy (MS-αCD20) receiving mRNA homologous boosting (n = 36). Pre-exposure increased humoral and CD4 T cellular responses in immunocompetent individuals. Novavax homologous boosting induced a significantly more robust serological response than mRNA boosting. MS-α CD20 had an intact IgA mucosal response and an enhanced CD8 T cell response to mRNA boosting compared with immunocompetent individuals. This enhanced cellular response was characterized by the expansion of only effector, not memory, T cells. The enhancement of CD8 T cells in the setting of B cell depletion suggests a regulatory mechanism between B and CD8 T cell vaccine responses.
- 1 March 2024
- Published by Oxford University Press (OUP) in ImmunoHorizons
- Vol. 8 (3) , 254-268
Open AccessSARS-CoV-2 Vaccine-Elicited Immunity after B Cell Depletion in Multiple Sclerosis
The impact of B cell deficiency on the humoral and cellular responses to SARS-CoV2 mRNA vaccination remains a challenging and significant clinical management question. We evaluated vaccine-elicited serological and cellular responses in 1) healthy individuals who were pre-exposed to SARS-CoV-2 (n = 21), 2) healthy individuals who received a homologous booster (mRNA, n = 19; or Novavax, n = 19), and 3) persons with multiple sclerosis on B cell depletion therapy (MS-αCD20) receiving mRNA homologous boosting (n = 36). Pre-exposure increased humoral and CD4 T cellular responses in immunocompetent individuals. Novavax homologous boosting induced a significantly more robust serological response than mRNA boosting. MS-α CD20 had an intact IgA mucosal response and an enhanced CD8 T cell response to mRNA boosting compared with immunocompetent individuals. This enhanced cellular response was characterized by the expansion of only effector, not memory, T cells. The enhancement of CD8 T cells in the setting of B cell depletion suggests a regulatory mechanism between B and CD8 T cell vaccine responses.
- 22 February 2023
- Published by Wiley in Arthritis & Rheumatology
- Vol. 75 (4) , 507-516
Association of Antibodies to Prevotella copri in Anti–Cyclic Citrullinated Peptide‐Positive Individuals At Risk of Developing Rheumatoid Arthritis and in Patients With Early or Established Rheumatoid Arthritis
Objective: Prevotella copri (P copri), a gut commensal, has been reported to be an immune‐relevant organism in individuals with rheumatoid arthritis (RA). This study sought to evaluate anti–P copri (anti–Pc) antibody responses in our participant cohorts and to determine when in the natural history of RA such responses develop.Methods: We analyzed serum levels of immunoglobulin A (IgA) and IgG antibodies from a 27‐kd protein of P copri (anti–Pc‐p27), an immunogenic P copri protein, in study participants at risk of developing RA, participants who transitioned to RA, participants with early RA (Pc‐p27 antibody levels in individuals stratified by RA‐related autoantibody status.Results: Overall, participants with RA had significantly higher IgA anti–Pc‐p27 antibody levels and trended toward higher IgG anti–Pc‐p27 antibody levels compared with matched controls. When stratified by early versus established RA, participants with early RA had median IgG anti–Pc‐p27 antibody levels that were overall higher, whereas median IgA anti–Pc‐p27 antibody levels were statistically significantly higher in participants with established RA compared with their matched controls. In the autoantibody‐specific analyses, the at‐risk population with anti–cyclic citrullinated peptide (anti‐CCP) antibodies, but not rheumatoid factor (RF), trended toward increased levels of IgG anti–Pc‐p27. Additionally, RA participants who were seropositive for both CCP and RF had significantly increased levels of IgA anti–Pc‐p27 antibodies and trended toward higher levels of IgG anti–Pc‐p27 antibodies compared with matched controls.Conclusion: Our findings support a potential etiologic role for P copri in both RA preclinical evolution and the subsequent pathogenesis of synovitis.
- 22 February 2023
- Published by Wiley in Arthritis & Rheumatology
- Vol. 75 (4) , 507-516
Association of Antibodies to Prevotella copri in Anti–Cyclic Citrullinated Peptide‐Positive Individuals At Risk of Developing Rheumatoid Arthritis and in Patients With Early or Established Rheumatoid Arthritis
Objective: Prevotella copri (P copri), a gut commensal, has been reported to be an immune‐relevant organism in individuals with rheumatoid arthritis (RA). This study sought to evaluate anti–P copri (anti–Pc) antibody responses in our participant cohorts and to determine when in the natural history of RA such responses develop.Methods: We analyzed serum levels of immunoglobulin A (IgA) and IgG antibodies from a 27‐kd protein of P copri (anti–Pc‐p27), an immunogenic P copri protein, in study participants at risk of developing RA, participants who transitioned to RA, participants with early RA (Pc‐p27 antibody levels in individuals stratified by RA‐related autoantibody status.Results: Overall, participants with RA had significantly higher IgA anti–Pc‐p27 antibody levels and trended toward higher IgG anti–Pc‐p27 antibody levels compared with matched controls. When stratified by early versus established RA, participants with early RA had median IgG anti–Pc‐p27 antibody levels that were overall higher, whereas median IgA anti–Pc‐p27 antibody levels were statistically significantly higher in participants with established RA compared with their matched controls. In the autoantibody‐specific analyses, the at‐risk population with anti–cyclic citrullinated peptide (anti‐CCP) antibodies, but not rheumatoid factor (RF), trended toward increased levels of IgG anti–Pc‐p27. Additionally, RA participants who were seropositive for both CCP and RF had significantly increased levels of IgA anti–Pc‐p27 antibodies and trended toward higher levels of IgG anti–Pc‐p27 antibodies compared with matched controls.Conclusion: Our findings support a potential etiologic role for P copri in both RA preclinical evolution and the subsequent pathogenesis of synovitis.
- Open Access
- 16 September 2022
- Published by Wiley in ACR Open Rheumatology
- Vol. 4 (11) , 974-982
Preferences and Insights for Participation in a Rheumatoid Arthritis Clinical Prevention Trial: A Mixed‐Methods Study
Objective: In rheumatoid arthritis (RA), anti–citrullinated protein antibodies (ACPA) can be elevated prior to inflammatory arthritis (IA). The potential to intervene in people with ACPA positivity underpins the development of prevention trials in RA. The Research Participation Influences Study examined factors influencing the decisions of individuals who are ACPA(+) to participate in a prevention trial using qualitative and quantitative methods.Methods: Individuals with ACPA positivity without IA were provided information regarding their risk for future RA, were provided a description of a clinical prevention trial using hydroxychloroquine, and were asked if they would participate in the trial. After agreeing to or declining participation, they were surveyed on what influenced their decision using Likert scales and open‐response questions.Results: Thirty‐nine individuals who agreed to trial participation (enrollees) and 31 individuals who declined (nonenrollees) completed surveys. Enrollees expressed greater perceived risk for RA and greater perception of benefit to themselves or others than nonenrollees. Nonenrollees expressed greater concern about medication effects and less personal or family experience with RA than enrollees. There was a higher proportion of first‐degree relatives (FDRs) of people with RA in enrollees versus nonenrollees (54% vs. 23%, P = 0.01).Conclusion: Enrollees were more likely than nonenrollees to be FDRs, exhibit stronger concern for personal risk for RA, and have less concern about adverse effects. Further exploration is needed to determine why these differences were present, including exploration of symptoms and the role of family history. Understanding these issues will better inform researchers and individuals who are candidates for prevention.
- 16 September 2022
- Published by Wiley in ACR Open Rheumatology
- Vol. 4 (11) , 974-982
Open AccessPreferences and Insights for Participation in a Rheumatoid Arthritis Clinical Prevention Trial: A Mixed‐Methods Study
Objective: In rheumatoid arthritis (RA), anti–citrullinated protein antibodies (ACPA) can be elevated prior to inflammatory arthritis (IA). The potential to intervene in people with ACPA positivity underpins the development of prevention trials in RA. The Research Participation Influences Study examined factors influencing the decisions of individuals who are ACPA(+) to participate in a prevention trial using qualitative and quantitative methods.Methods: Individuals with ACPA positivity without IA were provided information regarding their risk for future RA, were provided a description of a clinical prevention trial using hydroxychloroquine, and were asked if they would participate in the trial. After agreeing to or declining participation, they were surveyed on what influenced their decision using Likert scales and open‐response questions.Results: Thirty‐nine individuals who agreed to trial participation (enrollees) and 31 individuals who declined (nonenrollees) completed surveys. Enrollees expressed greater perceived risk for RA and greater perception of benefit to themselves or others than nonenrollees. Nonenrollees expressed greater concern about medication effects and less personal or family experience with RA than enrollees. There was a higher proportion of first‐degree relatives (FDRs) of people with RA in enrollees versus nonenrollees (54% vs. 23%, P = 0.01).Conclusion: Enrollees were more likely than nonenrollees to be FDRs, exhibit stronger concern for personal risk for RA, and have less concern about adverse effects. Further exploration is needed to determine why these differences were present, including exploration of symptoms and the role of family history. Understanding these issues will better inform researchers and individuals who are candidates for prevention.